Clinical

A review of insurance policies for Demodex blepharitis treatments, along with an analysis of the potential toxicities associated with these treatments.

Medical experts illustrate the impact of combination therapy for treatment of CLL and SLL.

Investigators observed an increase in the prevalence of Alzheimer disease in patients with diagnosed myasthenia gravis (MG), which indicates that MG is an independent risk factor for AD.

No causal association with psychiatric disorders was observed in patients with chronic obstructive pulmonary disease (COPD) without a smoking history, while ever-smokers with COPD had a greater risk of developing attention-deficit/hyperactivity disorder (ADHD).

A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets.

Light-to-moderate alcohol consumption seemed to provide greater protection against ischemic heart disease (IHD) mortality for individuals with higher socioeconomic status (SES) compared with those with lower SES, likely due to gaps in access to necessary care.

Strategies used during the COVID-19 pandemic to ensure continuity of care in people living with HIV can be used as a paradigm of adaptability during unexpected crises.

Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated.

The gene therapy delandistrogene moxeparvovec-rokl, also known as Elevidys (Sarepta Therapeutics) is indicated to treat Duchenne muscular dystrophy (DMD) in ambulatory patients aged 4 to 5 years, and Sarepta recently filed supplemental data with the FDA seeking to expand the labeled indication.

Several risk factors put patients with colorectal cancer at increased risk of anastomotic leakage after elective surgery.

Natasha Halasa, MD, MPH, of Vanderbilt University Medical Center (VUMC), discusses the active population-based surveillance that the New Vaccine Surveillance Network conducts.

With their closing thoughts, the panelists provide their key takeaways from this discussion surrounding the operationalization of bispecifics.

Experts underscore cost relief of bispecific antibodies via medication assistance programs.

Compared with patients with only chronic obstructive pulmonary disease (COPD), patients with COPD and anxiety and/or depression had increased clinical and economic burden.

Efficacy against chronic lymphocytic leukemia (CLL) was seen when tested as both a single agent and in combination with antitumor antibody.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses potential shifts in the lymphoma space in the year ahead.

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape.

In patients with high-grade ovarian cancer, an increased proportion of CD3+ CD137+ tumor infiltrating lymphocytes (TILs) correlated with favorable overall survival outcomes. However, proportions of CD3+ or CD3+ CD8+ TILs did not show significant associations with OS.

Dupilumab and topical corticosteroids can be used to treat symptoms in children with atopic dermatitis (AD).

The increased risk is likely due to the underlying cancer disease and adjuvant treatments, researchers find.

Pandemic-era policies that made it easier for patients to receive opioid addiction treatment will continue permanently; the Biden administration is facing pressure from Democrats and reproductive health groups to make sure the first OTC birth control pill is affordable; a FDA expert panel on Friday is set to resume the debate over how to make pulse oximeters more accurate for people with darker skin.

Although rates of opioid use disorder (OUD) are higher than previous estimates, OUD was relatively stable or decreasing over time in patients with HIV.

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.

The findings not only underscore the efficacy of 2 major interventions—Behavioral Activation Psychotherapy (BA) and Antidepressant Medication Management (MEDS)—but also support patient autonomy in choosing their preferred path to mental well-being.

This systematic review found COVID-19 disruptions on clinical outcomes in those with diabetes to be more pronounced for females, younger people, and those a part of racial and ethnic minority groups.